BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bettinger D, Knüppel E, Euringer W, Spangenberg HC, Rössle M, Thimme R, Schultheiß M. Efficacy and safety of transjugular intrahepatic portosystemic shunt (TIPSS) in 40 patients with hepatocellular carcinoma. Aliment Pharmacol Ther 2015;41:126-36. [PMID: 25329493 DOI: 10.1111/apt.12994] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Thimme R. EASL innovation award recipient 2022: Prof. Martin Rössle. J Hepatol 2022:S0168-8278(22)00344-0. [PMID: 35750547 DOI: 10.1016/j.jhep.2022.05.025] [Reference Citation Analysis]
2 Zhang X, Tsauo J, Tie J, Xue H, Zhao JB, Li JJ, Fang ZT, Guo WH, Li X. Emergent Transjugular Intrahepatic Portosystemic Shunt Creation for Acute Gastric Variceal Bleeding in Patients with Hepatocellular Carcinoma. J Vasc Interv Radiol 2022;33:702-6. [PMID: 35636835 DOI: 10.1016/j.jvir.2022.03.012] [Reference Citation Analysis]
3 Yan H, Qiu Z, Xiang Z, Feng K, Huang M, Gao F. TIPS improves outcomes in patients with HCC and symptomatic portal hypertension: a multi-institution experience. Cancer Imaging 2022;22. [DOI: 10.1186/s40644-022-00451-9] [Reference Citation Analysis]
4 Lu HL, Xuan FF, Luo YC, Qin X. Efficacy and safety of transjugular intrahepatic portosystemic shunt combined with transcatheter embolization/chemoembolization in hepatocellular carcinoma with portal hypertension and arterioportal shunt. Abdom Radiol (NY) 2021;46:5417-27. [PMID: 34302511 DOI: 10.1007/s00261-021-03214-5] [Reference Citation Analysis]
5 Schultheiß M, Bengsch B, Thimme R. [Hepatocellular Carcinoma]. Dtsch Med Wochenschr 2021;146:1411-20. [PMID: 34670284 DOI: 10.1055/a-1226-3047] [Reference Citation Analysis]
6 Chen X, Qiu ZK, Wang GB, Chen XL, Zhang FJ, Gao F. Effect of transjugular intrahepatic portosystemic shunt on transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis. Diagn Interv Radiol 2021;27:671-6. [PMID: 34318755 DOI: 10.5152/dir.2021.20358] [Reference Citation Analysis]
7 Tsauo J, Noh SY, Shin JH, Gwon DI, Han K, Lee JM, Jeon UB, Kim YH. Retrograde transvenous obliteration for the prevention of variceal rebleeding in patients with hepatocellular carcinoma: a multicentre retrospective study. Clin Radiol 2021;76:681-7. [PMID: 34140137 DOI: 10.1016/j.crad.2021.05.011] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Bisht RU, Liu MC, Koblinski JE, Kang P, Wong MN, Little EC. Is 70 the new 50? Complications and outcomes of transjugular intrahepatic portosystemic shunt in older versus younger patients. Abdom Radiol (NY) 2021;46:2789-94. [PMID: 32296899 DOI: 10.1007/s00261-020-02533-3] [Reference Citation Analysis]
9 Tsauo J, Tie J, Xue H, Zhao JB, Li JJ, Fang ZT, Guo WH, Li X. Transjugular Intrahepatic Portosystemic Shunt Creation for the Prevention of Gastric Variceal Rebleeding in Patients with Hepatocellular Carcinoma: A Multicenter Retrospective Study. J Vasc Interv Radiol 2021;32:963-9. [PMID: 33864909 DOI: 10.1016/j.jvir.2021.04.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Luo J, Li M, Wu C, Zhu D, Wang H, Huang M, Jiang Z. Transjugular intrahepatic portosystemic shunt versus endoscopic therapy for prevention of variceal rebleeding in patients with hepatocellular carcinoma meeting the Milan criteria. Eur J Gastroenterol Hepatol 2021;33:436-42. [PMID: 32398493 DOI: 10.1097/MEG.0000000000001750] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Yan H, Wang G, Zhu W, Feng K, Zhu W, Wu X, Qiu Z, Chen G, Jiang W, Zhang F, Gao F. Feasibility and clinical value of TIPS combined with subsequent antitumor treatment in HCC patients with refractory ascites. Transl Oncol 2020;13:100864. [PMID: 32950928 DOI: 10.1016/j.tranon.2020.100864] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Schultheiß M, Bettinger D, Thimme R, Rössle M. 30 Jahre transjugulärer intrahepatischer portosystemischer Shunt (TIPS) – Rückblick und Perspektive. Z Gastroenterol 2020;58:877-89. [DOI: 10.1055/a-1217-7866] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
13 Luo SH, Chu JG, Huang H, Yao KC. Safety and efficacy of transjugular intrahepatic portosystemic shunt combined with palliative treatment in patients with hepatocellular carcinoma. World J Clin Cases 2019; 7(13): 1599-1610 [PMID: 31367619 DOI: 10.12998/wjcc.v7.i13.1599] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
14 Zhang Y, Wu YF, Yue ZD, Zhao HW, Wang L, Fan ZH, He FL, Wang T, Liu FQ. Iodine-125 implantation with transjugular intrahepatic portosystemic shunt for main portal vein tumor thrombus. World J Gastrointest Oncol 2019; 11(4): 310-321 [PMID: 31040896 DOI: 10.4251/wjgo.v11.i4.310] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
15 Song Y, Li W, Xue H, Ruan L. Tei index is associated with survival in cirrhosis patients treated with transjugular intrahepatic portosystemic shunt. Echocardiography 2019;36:61-6. [PMID: 30506588 DOI: 10.1111/echo.14201] [Reference Citation Analysis]
16 Zhao H, Tsauo J, Zhang X, Gong T, Li J, Li X. Transjugular intrahepatic portosystemic shunt creation for portal hypertension in patients with hepatocellular carcinoma: A systematic review. Int J Gastrointest Interv 2018;7:167-71. [DOI: 10.18528/gii180026] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
17 Zhu X, Ran Z, Li W, Wang W, Zhu K, Huang W, Gao X. Method for Calculating the Bending Angle of Puncture Needle in Preoperative Planning for Transjugular Intrahepatic Portal Systemic Shunt (TIPS). Comput Math Methods Med 2018;2018:4534579. [PMID: 29977326 DOI: 10.1155/2018/4534579] [Reference Citation Analysis]
18 Bucsics T, Hoffman S, Grünberger J, Schoder M, Matzek W, Stadlmann A, Mandorfer M, Schwabl P, Ferlitsch A, Peck-Radosavljevic M, Trauner M, Karner J, Karnel F, Reiberger T. ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis. Liver Int 2018;38:1036-44. [PMID: 29091351 DOI: 10.1111/liv.13615] [Cited by in Crossref: 10] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
19 Qiu B, Li K, Dong X, Liu FQ. Transjugular Intrahepatic Portosystemic Shunt for Portal Hypertension in Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. Cardiovasc Intervent Radiol. 2017;40:1372-1382. [PMID: 28488102 DOI: 10.1007/s00270-017-1655-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
20 Rajoriya N, Tripathi D. Editorial: complications of TIPSS - consolidation of a decade of experience. Aliment Pharmacol Ther 2017;45:179-80. [PMID: 27910144 DOI: 10.1111/apt.13843] [Reference Citation Analysis]
21 Bettinger D, Schultheiss M, Boettler T, Muljono M, Thimme R, Rössle M. Procedural and shunt-related complications and mortality of the transjugular intrahepatic portosystemic shunt (TIPSS). Aliment Pharmacol Ther 2016;44:1051-61. [DOI: 10.1111/apt.13809] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 5.3] [Reference Citation Analysis]
22 Wannhoff A, Hippchen T, Weiss CS, Friedrich K, Rupp C, Neumann-Haefelin C, Dollinger M, Antoni C, Stampfl U, Schemmer P, Stremmel W, Weiss KH, Radeleff B, Katus HA, Gotthardt DN. Cardiac volume overload and pulmonary hypertension in long-term follow-up of patients with a transjugular intrahepatic portosystemic shunt. Aliment Pharmacol Ther. 2016;43:955-965. [PMID: 26919285 DOI: 10.1111/apt.13569] [Cited by in Crossref: 31] [Cited by in F6Publishing: 24] [Article Influence: 5.2] [Reference Citation Analysis]
23 Dariushnia SR, Haskal ZJ, Midia M, Martin LG, Walker TG, Kalva SP, Clark TW, Ganguli S, Krishnamurthy V, Saiter CK, Nikolic B; Society of Interventional Radiology Standards of Practice Committee. Quality Improvement Guidelines for Transjugular Intrahepatic Portosystemic Shunts. J Vasc Interv Radiol. 2016;27:1-7. [PMID: 26614596 DOI: 10.1016/j.jvir.2015.09.018] [Cited by in Crossref: 65] [Cited by in F6Publishing: 74] [Article Influence: 9.3] [Reference Citation Analysis]
24 Hassanien M, El-Talkawy MD, El-Ghannam M, El Ray A, Ali AA, Taleb HA. Predictors of In-Hospital Mortality in patients with hepatocellular carcinoma and Acute Variceal bleeding. Electron Physician 2015;7:1336-43. [PMID: 26516439 DOI: 10.14661/1336] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
25 Paul SB, Shalimar, Sreenivas V, Gamanagatti SR, Sharma H, Dhamija E, Acharya SK. Incidence and risk factors of hepatocellular carcinoma in patients with hepatic venous outflow tract obstruction. Aliment Pharmacol Ther. 2015;41:961-971. [PMID: 25809735 DOI: 10.1111/apt.13173] [Cited by in Crossref: 28] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
26 Zhao Y, Qi X, He S, Han G. Letter: TIPSS in hepatocellular carcinoma. Aliment Pharmacol Ther 2015;41:328. [PMID: 26146697 DOI: 10.1111/apt.13046] [Reference Citation Analysis]
27 Bettinger D, Knüppel E, Euringer W, Spangenberg HC, Rössle M, Thimme R, Schultheiß M. Editorial: TIPSS in patients with cirrhosis and hepatocellular carcinoma - authors' reply. Aliment Pharmacol Ther 2015;41:231. [PMID: 25511769 DOI: 10.1111/apt.13038] [Reference Citation Analysis]
28 Rowe IA, Tripathi D. Editorial: TIPSS in patients with cirrhosis and hepatocellular carcinoma. Aliment Pharmacol Ther 2015;41:230-230. [DOI: 10.1111/apt.13030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]